Volume 20, Issue 26 2308574
Research Article

SSK1-Loaded Neurotransmitter-Derived Nanoparticles for Alzheimer's Disease Therapy via Clearance of Senescent Cells

Wenbo Ji

Wenbo Ji

Department of Neurology, Second Afffliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Fengyang Road, Huangpu District, Shanghai, 200003 China

Search for more papers by this author
Honglei Zhou

Honglei Zhou

Department of General Surgery, The First Affiliated Hospital with Nanjing Medical University, Changle Road, Qinhuai District, Nanjing, 210006 China

Search for more papers by this author
Wendanqi Liang

Wendanqi Liang

Department of Neurology, Second Afffliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Fengyang Road, Huangpu District, Shanghai, 200003 China

School of Health Science and Engineering, University of Shanghai for Science and Technology, Jungong Road, Yangpu District, Shanghai, 200093 China

Search for more papers by this author
Weicong Zhang

Weicong Zhang

School of Pharmacy, University College London, Gower Street, London, W12 8LP UK

Search for more papers by this author
Baofeng Gong

Baofeng Gong

Department of Neurology, Second Afffliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Fengyang Road, Huangpu District, Shanghai, 200003 China

Search for more papers by this author
Tong Yin

Tong Yin

Department of Neurology, Second Afffliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Fengyang Road, Huangpu District, Shanghai, 200003 China

Search for more papers by this author
Jianjian Chu

Jianjian Chu

Department of Neurology, Second Afffliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Fengyang Road, Huangpu District, Shanghai, 200003 China

Search for more papers by this author
Jianhua Zhuang

Jianhua Zhuang

Department of Neurology, Second Afffliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Fengyang Road, Huangpu District, Shanghai, 200003 China

Search for more papers by this author
Jian Zhang

Corresponding Author

Jian Zhang

Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Clinical Pharmacy Innovatton Instttute, Shanghai Jiao Tong University School of Medicine, Kongjiang Road, Yangpu District, Shanghai, 200092 China

E-mail: [email protected]; [email protected]; [email protected]; [email protected]; [email protected]

Search for more papers by this author
Yi Luo

Corresponding Author

Yi Luo

New Drug Discovery and Development, Biotheus Inc, Keji 7th Road, TangjiawanTown, Zhuhai, 519080 China

Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Clinical Pharmacy Innovatton Instttute, Shanghai Jiao Tong University School of Medicine, Kongjiang Road, Yangpu District, Shanghai, 200092 China

E-mail: [email protected]; [email protected]; [email protected]; [email protected]; [email protected]

Search for more papers by this author
Yan Liu

Corresponding Author

Yan Liu

Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Clinical Pharmacy Innovatton Instttute, Shanghai Jiao Tong University School of Medicine, Kongjiang Road, Yangpu District, Shanghai, 200092 China

E-mail: [email protected]; [email protected]; [email protected]; [email protected]; [email protected]

Search for more papers by this author
Jie Gao

Corresponding Author

Jie Gao

Changhai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Changhai Road, Yangpu District, Shanghai, 200433 China

E-mail: [email protected]; [email protected]; [email protected]; [email protected]; [email protected]

Search for more papers by this author
You Yin

Corresponding Author

You Yin

Department of Neurology, Second Afffliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Fengyang Road, Huangpu District, Shanghai, 200003 China

Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Jimo Road, Pudong New District, Shanghai, 200120 China

E-mail: [email protected]; [email protected]; [email protected]; [email protected]; [email protected]

Search for more papers by this author
First published: 01 March 2024
Citations: 6

Abstract

Age is a significant contributor to the onset of AD. Senolysis has been recently demonstrated to ameliorate aging-associated diseases that showing a great potential in AD therapy. However, due to the presence of BBB, the anti-AD activity of senolytics are significantly diminished. SSK1 is a prodrug that can be activated by β-gal, a lysosomal enzyme commonly upregulated in senescent cells, and thus selectively eliminates senescent cells. Furthermore, the level of β-gal is significantly correlated with conventional AD genes from clinical sequencing data. SSK1-loaded neurotransmitter -derived lipid nanoparticles are herein developed (SSK1-NPs) that revealing good BBB penetration and bioavailability of in the body. At the brain lesion, SSK1-NP treatment significantly reduces the expression of genes associated with senescence, induced senescent cells elimination, decreased amyloid-beta accumulation, and eventually improve cognitive function of aged AD mice. SSK1-NPs, a novel nanomedicine displaying potent anti-AD activity and excellent safety profile, provides a promising strategy for AD therapy.

Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

Research data are not shared.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.